About us

Global Morpho Pharma

Global Morpho Pharma is a French start-up company created in 2018 that aims at developing and distributing GMP-grade radioisotopes. We are developing innovative equipment and building efficient supply chains to enable our partners worldwide to manufacture or source nca Lu-177 and other radioisotopes of interest.
We are dedicated to improving the accessibility and supply security of medical radioisotopes for the benefit of patients by providing convenient solutions to the rapidly expanding nuclear medicine ecosystem.

The Blue Morpho (Morpho menelaus) is not only one of the largest butterflies, but a symbol of beauty, perfection and freedom. Its iridescent metallic blue wings are reminiscent of the blue color of the Cherenkov Effect, the only visible way to recognize radioactivity.

The team

François Zimmermann
Adrien Reymond
Zarema Bersanova
Purchasing & Sales Coordinator

The founders

Five experts of the nuclear medicine field came together with a common vision about the future of radiotherapeutics and radiotheranostics. With a cumulated experience of over 100 years in nuclear medicine, this group anticipated a very fast growth of this field and identified the challenges posed by industrialization of radiopharmaceutical drug manufacturing. Success of this industry, one of the most complex and regulated industry in the world, requires manufacturing quality, supply security and distribution reliability. The foundation of Global Morpho Pharma aims to address the needs of the pharmaceutical industry by improving the accessibility and supply security of medical radioisotopes for the benefit of patients.

Pierre-Marie Lemer - Global Morpho Pharma

In 1995, Pierre-Marie-Lemer became Managing Director of Lemer Pax, a company founded in 1970. He has been President of the firm since 2005. As an industrial technology specialist, Lemer Pax employs 75 people across two facilities. The company has been a partner of France’s Atomic Energy Commission (CEA) since its creation. Lemer Pax conceives, designs and manufactures innovative radioprotection solutions for use in the fields of medicine, scientific research, industry and nuclear protection. A historic leader in the French nuclear medicine sector, Lemer Pax is the first company in the world to have designed and developed a mobile unit for the preparation and injection of high energy radiopharmaceuticals.
With over 70 patents registered in the past four years, under Pierre-Marie Lemer’s guidance Lemer Pax has become the world’s leading source of innovation in the field of radioprotection.

Pierre-Marie Lemer
Chairman, Co-founder
Richard-Zimmermann - Global Morpho Pharma

Richard Zimmermann is a chemistry engineer, PhD in Organic Chemistry (Strasbourg), who spent 15 years working in R&D with the Conventional Pharmaceutical Industry with Beecham (cardiology) later Solvay Pharma (immunology, gastroenterology) before joining in 1998 the Radiopharmaceutical Industry as R&D Director with CISbio international (Saclay). He was also in charge of building the European PET/FDG manufacturing network for CIS/IBA and VP BD for IBA Molecular.
Since 2012, he works for his own consulting company, Chrysalium, specialized in radiopharmaceuticals industrialization. He is cofounder of MEDraysintell, president of the Oncidium Foundation, initiator of rad4med.be, president of ANMI and interim GM of Global Morpho Pharma.

Richard Zimmermann
Valérie Chevreul - Global Morpho Pharma

Valérie Chevreul graduated from a Business School and a Superior Financial Diploma. She started her career as a financial auditor in chartered accountants & legal auditors firms in Halifax (England) and Paris. After this experience, she worked four years as internal auditor for Total Exploration & Production in the Hague (The Netherlands).
In 2007, she integrated Lemer Pax company as financial & human resources manager, very quickly she became general manager and then shareholder. She is also one of the founder member of Global Morpho Pharma.

Valérie Chevreul
Dmitryi Linchevsky - Global Morpho Pharma

Dmitriy Linchevsky graduated from Hofstra University, Business computer information system, and started his work with marketing researches eventually moved to the area of high-technology equipment markets. He was working as CFO of Komfinservice company from 2001.
After 2007 Dmitry came to the conclusion that nuclear technologies area is one of the most promising spheres with a growing number of applications and came with the initiative to start work with radiation protection equipment, equipment for nuclear medicine and research and developments in hot cells equipping. Now he is developing this area.

Dmitriy Linchevsky

Alexander Lintchevsky graduated from Tashkent Institute of Engineers of Rail Transport, the Faculty of Construction of Railways, Bridges and Tunnels. He, as an engineer, worked in large-scale construction projects. Later he was the owner of commercial structures in the spheres of construction, construction machinery and high-technology equipment.
Today he owns several companies working in the spheres of electrical equipment, innovative technical developments, equipment for nuclear production and nuclear medicine.

Alexander Lintchevsky

Our partners

Contact us

To find out more about how to know and exercise your rights, like the withdrawal of your consent to use submitted datas, please check out our privacy policy.

Message Sent!
Thank you for your interest.
We are doing our best to get back to you shortly,
The Global Morpho Pharma team.
Sorry network issue,
please try again
or send us an email:
Thank you